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Abstract  
Although evidence exists to suggest that post MI mortality is reducing in parallel with 
advancements in cardiology practice, ‘optimal medical management’ and risk factor 
control of patients with coronary heart disease (CHD) has been referred to as being 
sub-optimal compared to that shown to be effective in clinical research. With 
numerous treatment methods available for managing CHD, continuous analysis is 
required to ascertain which treatment methods are most beneficial in reducing 
mortality and improving outcomes for patients following a diagnosis of CHD. 
Additionally, increasing numbers of patients commence medical therapy with surgical 
intervention deferred. It is therefore imperative that patient treatment is optimised 
through adherence to clinical guidelines. This paper aims to explore the current 
standpoint on treatment options for CHD whilst analysing the extent to which 
evidence based guidelines translate into clinical practice. This will include the 
discussion of patient compliance and community follow up and the impact these 
factors have on outcomes for patients with CHD. This will be established by first 
exploring the effectiveness of treatment methods for CHD before discussing the use 
of cardiac rehabilitation as a resource for further improving outcomes following 
treatment. 
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Introduction  
Cardiovascular disease (CVD) remains the leading cause of death in the UK, 
responsible for 46,000 premature deaths in 2010 (British Heart Foundation, 2012). 
However, post myocardial infarction (MI) and CVD mortality has reduced since 2002 
with 30 day fatality reported as reducing from 42% to 32.1% in 2010, in males and 
from 42.2% to 29.9% in females (Smolina et al., 2012). This study captured 
individuals admitted to hospital with acute MI although it does not represent 
individuals who may present to private hospitals or individuals having had a ‘silent 
MI’ that is not detected immediately. The decline in mortality nevertheless could be 
explained by advancements in both primary and secondary prevention however, 
Smolina et al. (2012) did not state whether individuals admitted to hospital had a pre-
existing diagnosis of CVD. The study period does however coincide with 
advancement in medical treatment of coronary heart disease (CHD) including the 
widespread, revolutionary introduction of percutaneous coronary interventions (PCI) 
to treat ST-segment elevation myocardial infarction (STEMI), rather than the use of 
fibrinolysis (Gershlick et al., 2013).   
 
With a continuing requirement to conform to evidence based practice, in conjunction 
with the likelihood that cardiology will continue to advance in the future, it is 
important to assess how well treatments are achieving their aims in reducing cardiac 
related mortality and improving quality of life. Gershlick et al. (2013) question how 
realistic evidence based targets are in reality, in busy hospital departments such as 120 
minutes from emergency response to balloon deployment for treatment of STEMI 
(National Institute for Health and Care Excellence [NICE], 2013). It is also suggested 
that clinical treatment may be sub-optimal compared to what is known to be effective 
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from research, particularly when individuals live in rural and remote locations. 
Prolongation of time to angioplasty has however been associated with worsening 
myocardial function and mortality with De Luca et al. (2004) reporting every thirty 
minute delay in reperfusion following MI to be associated with an 8% excess annual 
mortality. However, there is a lack of a randomised controlled trial to analyse the full 
extent of primary PCI time delay by comparing outcomes to that of traditional 
fibrinolysis treatment.  
 
Additionally, with a rapid increase in prescriptions of cardio-protective medications 
over recent years, one would expect this to contribute to the reduction in mortality. 
Kotseva et al. (2009) investigated the extent to which the Joint European Guidelines 
on CVD Prevention (De Backer at al., 2003) were adhered to and whether medical 
therapies were reducing risk factors in individuals diagnosed with CHD across 22 
European countries. Interestingly, 56% of patients remained hypertensive six months 
after diagnosis and 51% had total serum cholesterol above 4.5mmol/l, suggesting sub-
optimal risk factor control. When investigated further, as few as 31% of patients were 
prescribed a beta-blocker and only a quarter of patients prescribed anti-hypertensive 
medication achieved target blood pressure levels, therefore remaining at risk of 
secondary events. This raises question to how effectively patients are followed up to 
ensure they receive appropriate medications, at evidence based doses. Additionally, 
patients may not be compliant with their drug regimes, a concept that will be explored 
as part of this review.  
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Optimal medical management of CHD      
The term ‘optimal medical management’ refers to a combination of lifestyle 
modifications including physical activity and dietary behaviours. This is in addition to 
a recommended drug regime aimed to reduce mortality and risk of cardiovascular 
events whilst increasing exercise capacity and improving quality of life (Braunwald et 
al., 2000). Additionally, treatment for CHD includes medical management with or 
without revascularisation with either PCI (with or without stenting) or coronary artery 
bypass grafts (CABG). Despite well recognised guidance on the management of 
CHD, a ‘one size fits all approach’ does not seem feasible with such a complex 
process and controversy therefore exists as to which treatment options are most 
beneficial in reducing mortality whilst being cost effective.  
 
CABG has demonstrated improved survival over medical treatment for patients with 
left main stem (LMS), triple vessel disease and/or diabetes. LMS disease carries the 
worst prognosis of all coronary lesions largely due to the vast area of myocardium 
covered. In untreated cases, the prognosis of such disease is reported as 37% at 3 
years (Taggart et al., 2008). However, since the large scale introduction of PCI and 
advancements to the procedure with drug eluting stents, more complex diseases 
including that of the LMS are being treated with PCI as the primary choice of 
revascularisation. Recent research by Serruys et al. (2009) does however demonstrate 
CABG as the treatment of choice in three vessel or LMS disease and report higher 
rates of adverse events and repeat revascularisation for individuals undergoing PCI. 
However, the study fails to report on the degree of medical management that 
participants were receiving and whether this was equivalent for both groups. 
Additionally, the study does not comment on whether the CABG procedures were 
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performed on or off-pump despite the recognition that off-pump CABG reduces the 
risk of complications, particularly stroke, with a reduced procedure time. Although to 
date there is a lack of long-term data to confirm such benefits in relation to reducing 
overall CHD mortality however it is apparent that despite PCI producing comparable 
results in some patients, CABG remains the standard of care for complex disease. 
 
Furthermore, studies comparing CABG to medical management report by 10 year 
follow up that 41% of patients started on medical therapy go on to receive 
revascularisation with CABG (Yusuf et al., 1994), suggesting medical treatment in 
some cases delays the inevitable. This study is however rather dated as it was 
conducted between 1972 and 1984 whilst the American Heart Association guidelines 
have been modified numerous times since. The study also pre-dates the use of off-
pump CABG as on-pump procedures were performed whilst the heart was stopped. 
Concerns about the accuracy of grafting techniques of surgeons whilst the heart is still 
beating has been overruled by evidence that experienced surgeons demonstrate 
excellent results from this procedure although the risk of death (1 – 2%) is suggested 
to be equivalent for both procedure methods (Shekar, 2006). Further proposed 
benefits of off-pump CABG include reduced risk of postoperative atrial fibrillation, 
lower risk of stroke, neuro-cognitive and organ dysfunction. However research to date 
has only confirmed the reduced risk of postoperative atrial fibrillation with off-pump 
procedures (Møller et al., 2008), therefore larger trials are needed before concluding 
that the procedure also reduces the risk of death, MI and stroke. 
 
On the contrary, Boden et al. (2007) report a high initial success rate with PCI but 
further comment that 34% of patients have angina one year after the procedure due to 
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residual CHD resulting from either re-stenosis or deterioration of the disease in other 
coronary lesions. They further report that PCI failed to produce initial benefits of 
reducing risk factors and cardiovascular events compared to that of medical 
management. The study does however report on the utilisation of optimal medical 
therapy in both treatment groups whereas previous research (Folland et al., 1997 & 
Pitt et al., 1999) failed to apply aggressive medical therapy to individuals undergoing 
revascularisation and subsequently reported that PCI produced no significant benefit 
over medical therapy in single or two-vessel CHD. Additionally, the study by Boden 
et al. (2007) was conducted between 1999 and 2004, prior to the introduction of drug 
eluting stents. Stent design and technology has also rapidly advanced with the benefit 
of reducing the likelihood of vessel re-stenosis. Drug eluting stents antagonise cellular 
reactions to prevent in-stent re-stenosis but it has been suggested that they do not 
impact on survival or prevent MI in single vessel disease compared to treatment with 
bare metal stents (Roiron et al., 2006). However, the use of drug eluting stents has 
rapidly increased in many countries due to reduced need for repeat interventions. 
Although research on rates of repeat intervention appears to fail to distinguish 
between revascularisation due to re-stenosis and that of disease progression in other 
lesions which PCI cannot alter, therefore the benefits stated are likely over-
exaggerated. Nevertheless, in the UK in 2003, 17% of all stents used during PCI were 
drug eluting which rose further to 62% in 2005 (NICE, 2008). 
 
Furthermore, lower success rates with PCI and stents appears common in patients 
with diabetes, due to the complex nature of the coronary anatomy, including longer 
lesion lengths but smaller vessel diameter, in addition to exaggerated inflammatory 
processes. Given that Type 2 diabetics have a twofold increased risk of developing 
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CHD (Giorda et al., 2004), this has historically led to CABG being the preferable 
procedure in these patients, particularly for multi-vessel disease due to improved 
survival and reduced need for repeat revascularisation (Mak, 2012). However, drug 
eluting stents have also been shown to produce more favourable outcomes in patients 
with diabetes (Garg et al., 2008) than bare metal stents, although this study did not 
further compare differences in outcomes between insulin and non insulin-dependant 
diabetics. Voudris et al. (2011) report a higher incidence of multi-vessel CHD among 
diabetics requiring insulin and a higher rate of revascularisation or CABG following 
PCI with drug eluting stents compared to non insulin-dependant diabetics. However it 
is not clear whether the rate of revascularisation is due to re-stenosis or disease 
progression therefore the long term effectiveness of drug eluting stents with insulin-
dependant diabetes has been shown to be lower. The introduction of drug eluting 
stents does not appear to bridge the gap compared to treatment for non-diabetics, 
demonstrating the importance of individualised patient centered care and consultation 
prior to treatment selection.  
 
Research such as Boden et al. (2007) also lacks detail on the nature of follow up 
patients receive to assess the effectiveness of medication regimes. With the aim of 
optimal medical management being to slow down the progression of the disease, it 
can be questioned whether individuals undergoing revascularisation are not only 
receiving the correct pharmacotherapy but that this is also of an optimal dose to 
produce significant benefit. Revascularisation with either PCI or CABG only 
addresses the lesions that have become obstructive to a degree that results in a patient 
becoming symptomatic. A lumen stenosis greater than 75% has historically defined 
clinically significant disease largely due to reproducible symptoms of angina during 
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stress testing correlating to such a degree of stenosis. However, research now suggests 
that as few as 14% of clinically incapacitating events occurs at a lumen stenosis of 
≥75% (Maseri & Fuster, 2003). Nevertheless, patients with even mild CAD often 
have more extensive atherosclerosis, including that of other territories, even if this is 
not detected on coronary imaging. Therefore patients are vulnerable to occlusive 
events in carotid and femoral arteries, increasing the risk of stroke or peripheral 
vascular disease. Optimal medical management additionally treats the underlying 
disease in the entire vasculature (Lamy, Natarajan & Yusuf, 2011) therefore it may be 
more pertinent to view the treatment options of medical management with or without 
revascularisation as complimentary rather than competing as isolated management 
strategies. 
 
Achieving safe levels of optimal medical management, particularly in patients 
following acute MI becomes challenging when hospital stays are shortened, which 
may be more cost-effective, relieving some of the economic burden faced by the NHS 
but potentially to the detriment of treatment optimisation. The NICE (2013) 
recommend the initiation of an angiotensin-converting enzyme (ACE) inhibitor, beta-
blocker, dual anti-platelet therapy and statin following acute MI. Stewart, 
Woothipoom & Townend (2010) conducted a retrospective study of hospital 
discharge summaries for patients post MI and report 75.1% of patients as having been 
prescribed and discharged on sub-optimal doses of ACE-inhibitors and beta-blockers 
however, nearly all received optimal doses of statin and anti-platelet therapy. Stewart, 
Woothipoom & Townend (2010) defined a criteria for the optimal dose of medication 
however failed to provide evidence for the selection of the criteria in order to 
demonstrate that the doses have been shown to reduce post-MI mortality rates. This 
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nevertheless highlights a discrepancy in the optimisation of drugs with a range of 
possible doses, compared to that of drugs with fewer options.  
 
Where possible, beta-blockers and ACE-inhibitors should be prescribed and increased 
in a similar fashion to that demonstrated as effective in clinical research (NICE, 
2013). ACE-inhibitors have been shown to reduce mortality and reduce the likelihood 
of developing heart failure post-MI however the NICE guidelines do not recommend 
a standardised timescale for its initiation and titration. Pfeffer et al. (1997) report that 
initiation of ramipril, titrated up to its maximal dose within 60 hours post-MI 
improves left ventricular remodelling, providing a survival benefit over initiating 
ramipril 14 days after the event. Furthermore, the difference in speed of initiation and 
subsequent outcomes was significant and warranted early termination of the study. 
They additionally attempted to quantify the benefits of a low dose ACE-inhibitor 
however this failed to produce benefits proportional to the maximal dose, although the 
reliability of the measurement can be questioned as the dose prescribed to patients 
was half that of the lowest clinically recognised and prescribed dose. If treatment is 
sub-optimal, there is an increased risk that more patients will manifest symptoms of 
heart failure and have a greater risk of fatal and non-fatal ischemic and arrhythmic 
events, an important concept considering improvements to the treatment of MI have 
led to an increased burden of heart failure due to the increased likelihood of patients 
surviving but with damaged myocardium. The underlying cause in the majority of 
cases for developing heart failure includes myocardial necrosis with subsequent 
ventricular remodelling including left ventricular wall thinning, chamber dilation and 
compensatory hypertrophy (Cowie, Lacey & Tabberer, 2005). Therefore in order to 
reduce the chance of progression from acute MI to heart failure, patients need to 
J02482 
 12
receive early reperfusion followed by optimal medical management both in hospital 
and in the community setting as advised in evidence based guidelines. 
 
It is also well established that beta-blockers improve survival following MI 
(Freemantle et al., 1999), with the aim to reduce heart rate, myocardial oxygen 
demand and arrhythmias. However, Freemantle et al. (1999) report a variance in the 
time of commencement of the medication in their systematic review in addition to 
varying methods for administration including oral and intravenous. The optimal 
timing of initiation of beta-blockers in secondary prevention does appear unclear 
however in the clinical setting, delayed initiation of beta-blockers has been reported to 
vary from 2 hours to 28 days (NICE, 2013). Research does however demonstrate that 
beta-blockers are increasingly prescribed post-MI and Goldberger et al. (2010) report 
93.2% of patients diagnosed with MI as receiving beta-blocker therapy. However, 
they report that only 17% achieved more than 50% of the target dose by hospital 
discharge with the majority (36.5%) receiving only 25% of the target dose. 
Community follow up was also assessed and reported that 3 weeks post discharge 
54% of patients were still taking less than 25% of the medication dose demonstrated 
to be effective. This demonstrates inconsistencies in the speed of titration of beta-
blockers and ACE-inhibitors with clinically effective doses commonly not reached 
prior to discharge whilst additionally highlighting the potential underutilisation of the 
community setting to ensure patients are appropriately followed up. 
 
Recommendations on the up-titration of the medications have since been introduced 
to the NICE guidelines (2013) which state that hospital discharge summaries should 
include information on the titration of medications with the aim of ensuring 
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appropriate alteration in the community to achieve optimal benefit for the patient. The 
environment of a busy hospital department under increasing workload pressures may 
explain to some extent why this does not necessarily translate into practice. Stewart, 
Woothipoom & Townend (2010) report on interventions to improve doctors’ 
instructions on hospital discharge summaries however, a six week intervention 
promoting adherence to the NICE guidelines, utilising posters on hospital computers 
with instructions on therapeutic doses failed to produce a significant improvement to 
doctors’ comments. It was reported that this is likely due to confounding variables 
such as time constraints and the likelihood that discharge summaries are completed by 
junior doctors with limited experience of cardio-protective medications. 
 
However, full responsibility cannot be placed on acute hospital trusts for the lack of 
medication titration as patients who are under the care of a specialist in an acute trust 
may find that their general practitioner is reluctant to address alterations to 
medications, rather opting to leave the prescription for the patient’s next review with 
the specialist. Although, such appointments can be months after treatment, leaving the 
patient on sub-optimal management for a substantial amount of time, at arguable the 
most crucial time in the patient’s recovery. Additionally, community and general 
practitioners may find difficulty in managing the adverse effects associated with dose 
titration as 80% of individuals with cardiovascular disease attending cardiac 
rehabilitation have at least one other illness (NACR, 2013) and therefore often require 
multiple medications, some of which contraindicate the use of certain cardio-
protective medications. Furthermore, patient adherence may be associated with up-
titration as increases to medication may be viewed negatively or seen as necessary 
because their condition is deteriorating. This highlights the importance of education 
J02482 
 14
so that patients are aware of the benefits of optimisation from initiation of medical 
therapy. Although, Horne & Weinman (1999) report a positive correlation between 
beliefs that medications are necessary to maintain health and adherence however, 
education and number of medications taken did not predict adherence. Alm-Roijer et 
al. (2004) also found correlations between patients with greater knowledge of CHD 
risk factors and greater self-reported compliance with lifestyle changes but not with 
compliance of medications. 
 
Shah et al. (2009) report medication adherence to progressively decrease over time 
with beta-blocker use reducing from 79% to 48% and ACE-inhibitors from 73% to 
43% over a 3 year period. Enrolment in cardiac rehabilitation has however been 
associated with a greater likelihood of continuing cardio-protective medications post-
MI and this has been reported to be independent of the number of rehabilitation 
sessions attended. Although the study does not establish why medications were 
discontinued and a proportion of patients may have stopped the medications for 
genuine reasons such as by instruction from a general practitioner or because they 
could not tolerate the medication. Further research on compliance, although self 
reported, found that at six month discharge of 18,809 post-NSTEMI patients, 78.1% 
were taking beta blockers, 89.8% ACE inhibitors and 94.7% anti-platelets (Chow et 
al., 2010). The premature discontinuation of dual anti-platelet therapy in patients 
particularly with drug eluting stents can increase the likelihood of stent thrombosis 
and subsequent adverse outcomes (Egred, Andron & Perry, 2008) therefore the NICE 
(2013) guidelines state the continuation of dual anti-platelet therapy for 12 months 
however, research is underway comparing outcomes with randomisation of patients to 
shorter term dual therapy. 
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Cardiac Rehabilitation 
There is nevertheless the opportunity to promote adherence to drug therapy during 
cardiac rehabilitation and despite the fact that 13% of patients referred to a cardiac 
rehabilitation programme do not take it up (NACR, 2013), the uptake is gradually 
improving. The British Association for Cardiovascular Prevention and 
Rehabilitation’s (BACPR, 2012) core components stipulate that the use of and 
adherence to cardio-protective medication should be assessed in order to facilitate the 
up-titration of medication with the aim of achieving evidence-based dosages. They 
further state this should include an assessment of the patients’ beliefs, which has been 
shown to influence adherence to a greater degree than socio-demographic and clinical 
factors (Horne & Weinman, 1999). This emphasises the importance of cardiac 
rehabilitation as an independent component to delivering optimal medical 
management. 
 
Comprehensive rehabilitation has been shown to reduce all-cause mortality by 13% 
and cardiac specific deaths by 26% (Heran et al., 2011). However West et al. (2012) 
report higher mortality rates for patients attending rehabilitation and no significant 
difference in mortality compared to those who do not attend. Although, despite the 
study being published in 2012, it was conducted between 1997 and 2000 and therefore 
failed to achieve their objective of assessment of a new era of MI management as 
current practice has evolved since as previously discussed, including early 
intervention and individualised rehabilitation. Additionally, West et al. (2012) failed 
to comment on the proportion of this mortality that was cardiac specific and further 
lack detail in their publication on the format of the rehabilitation programmes that 
were offered including the dose of the exercise component. Therefore it cannot be 
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conferred whether the programmes assessed were conforming to the BACR standards 
of that time. The safety of the exercise programmes included in the study can 
therefore be questioned as the author makes no reports of exercise testing protocols to 
ensure patient safety to exercise. West et al. (2012) further reports that at 12 month 
follow up only 65% of patients were taking statins, 43% ACE-inhibitors and 61% a 
beta-blocker. This demonstration of sub-optimal medical management of post-MI 
patients may in part explain the higher mortality rate observed. It is likely that a 
number of these patients may demonstrate symptoms of angina, demonstrating the 
importance of exercise stress testing prior to commencement of an exercise 
programme to establish whether symptoms are reproducible on exertion.  
 
It can be argued that medical management should optimise exercise capacity without 
restrictions to exercise programmes such as that of ischemic thresholds as 
recommended by the American College of Sports Medicine (2014). Although, 
research is emerging that suggests that these guidelines require evaluation due to the 
limitations that they can place on patients with low ischemic burdens and resultant 
deprivation of the benefits of exercise. Noël et al. (2007) demonstrate that repeated 
exercise training above such a threshold has been well tolerated without evidence of 
myocardial injury, compromise to left ventricular function or inducible significant 
arrhythmias. However, this randomised controlled trial was relatively small therefore 
more evidence is needed from larger evaluations before the guidelines and current 
practice can be modified. 
 
Nevertheless, research which questions the value of cardiac rehabilitation will 
ultimately impact on referrals. Ghisi et al. (2013) highlight patient benefit and 
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programme quality as influential factors on a specialist’s decision to refer, with a G.P 
less likely to refer than a cardiologist. Research additionally demonstrates the strength 
of the medical professionals’ recommendation as influential on patients’ decisions to 
enrol onto programmes. Given the new era of primary angioplasty it is important to 
ensure that patients are encouraged to attend rehabilitation as opposed to believing 
that their condition has been treated with a ‘quick fix’ that does not require lifestyle 
and pharmacological intervention to treat the disease. This is supported by Barber et 
al. (2001) who report that patients who undergo CABG are more likely to be referred 
and attend rehabilitation than those who receive PCI or medical management post-MI. 
They further report that patients were more likely to participate if they have an 
appointment to see a cardiac surgeon or cardiologist arranged at hospital discharge, 
suggesting that rehabilitation is then viewed as part of their overall treatment prior to 
follow up. 
 
When reviewing research such as Maron et al. (2010) who found no significant 
difference in achievement of risk factor targets when comparing optimal medical 
therapy (including lifestyle and pharmacological) with and without angioplasty in 
patients with stable CHD, it is clear that medications were provided at no cost to the 
patient which is likely to influence adherence as in clinical practice, prescriptions are 
heavily based on cost. Furthermore, Maron et al. (2010) did aggressively target 
pharmacotherapy and this was adjusted at follow up if patients were not achieving 
targets, by a nurse case manager. For patients attending cardiac rehabilitation, the 
BACPR (2012) recommend an initial appointment with a health professional within 
two weeks of discharge which could provide an ideal opportunity to assess adherence 
and discuss whether it is appropriate for the titration of medications, similar to that 
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demonstrated to be effective in clinical research. Although to date, there is a lack of 
information, in the U.K on whether rehabilitation programmes are able to offer such a 
service. The NACR (2013) reports on the staffing components of rehabilitation 
programmes across the UK but it does not identify whether services offer nurse led 
prescribing clinics.  
 
Conway & Ferguson (2011) do however report on a UK cardiac rehabilitation 
programme where all specialist nurses are supporting in completing a non-medical 
prescribing course to enable the service to conform to BACPR (2012) standards and 
ensure medications are reviewed and titrated safely by a competent practitioner. 
Medications are reviewed five days after hospital discharge and within three weeks 
the patient is seen by a nurse prescriber to up-titrate beta-blockers and ACE-inhibitors 
and prescribe anti-anginal medication, where appropriate. Additionally, at the end of 
an eight week, phase III programme, the medications are re-reviewed, promoting a 
patient-centered approach to care. As this service is integrated into the routine care 
patients receive, this is expected as part of their treatment which may assist with 
adherence to a long term drug regime. An evaluation of the service reports that 
patients valued the level of care received and staff valued the opportunity to address 
issues such as why patients discontinue medications, uncontrolled hypertension and 
raised heart rates but additionally this highlighted instances whereby medications 
were reduced due to abnormal liver or kidney function or intolerable side effects 
which research such as Shah et al. (2009) fails to take account of.  
 
Despite this providing a positive example of how services can link research with 
practice, this provides only one example from a single hospital department therefore 
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further research is needed on how well nurse prescribing services integrate with the 
standard practice of cardiac rehabilitation. Despite medication reviews being 
recognised in the BACPR standards, the NACR does not recognise pharmacotherapy 
assessment and/or education as an independent programme component that warrants 
evaluation. Additionally, the NACR collate data on the medications patients are 
taking but does not attempt to establish the dose of recommended medications to 
determine, in conjunction with assessment measures, whether patients are receiving 
optimal cardio-protective therapies. Even the National Service Framework for CHD 
(Department of Health, 2000) focuses heavily on lifestyle behaviours as part of 
cardiac rehabilitation without emphasising a pharmacotherapy element as part of this. 
Although, this was published prior to the updated NICE guidelines whereas the 
national need to raise awareness of the sub-optimal management of patients with 
CHD appears to have begun. 
 
Conclusion  
This review has highlighted the need to evaluate clinical practice and ensure patients 
receive the benefits derived from clinical research in order to facilitate the 
continuation of improved mortality rates post-MI. In the long term, sub-optimal doses 
have been shown to have no affect on the control of angina symptoms and can in fact  
increase rates of hospital re-admission and further cardiac events (NICE, 2013). It is 
however clear that the management of CHD is multifaceted and clinical decisions 
need to balance adherence to guidelines with judgments based on each individual 
patient including that of socio-economic factors. With medical therapy and symptom 
management more commonly opted for following initial diagnosis of CHD, it is 
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imperative that this treatment is as optimal as tolerated to give patients the best chance 
of avoiding further intervention whilst improving quality of life. 
 
There does also appear to be strong evidence for the utilisation of an independent 
nurse prescribers in cardiac rehabilitation however before such a service is likely to be 
commissioned, services need to demonstrate how well patients’ cardio-protective 
therapies are currently managed before looking for cost-effective ways to drive 
service improvement. It would therefore be worthwhile to assess the level of optimal 
medical management patients who are attending cardiac rehabilitation are receiving 
and investigate whether sub-optimal management can be highlighted by the 
demonstration of symptoms of angina and signs of ischemia by means of ST-segment 
depression during exercise stress testing. It would additionally be useful to analyse 
whether differences exists in the management of patients with medications and those 
who have additionally undergone revascularisation. Such research could also help to 
assess whether patients who are asymptomatic still demonstrate signs of insufficient 
myocardial perfusion which would not be detected unless the patient partakes in an 
exercise stress test as part of their cardiac rehabilitation. Furthermore, as evidence 
based practice is constantly evolving, research such as this may provide valuable 
information on whether the format of cardiac rehabilitation in terms of the exercise 
testing and prescription components could be further improved with the addition of an 
exercise stress test as a routine standard of care as opposed to functional capacity 
testing procedures. 
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To my knowledge, this is an original evaluation and research to date has not 
addressed the medical management of patients by reviewing exercise test information 
particularly that of ST-segment depression. It is therefore felt that the British Journal 
of Cardiology would be the most appropriate journal for the evaluation’s publication. 
Additionally, members of the BACPR are subscribed to the journal and would 
therefore be able to access the article which has been written to enable service 
improvement at Wirral Heart Support Centre but this may additionally benefit the 
delivery of cardiac rehabilitation services nationwide. 
 
Abstract     
‘Optimal medical management’ aims to reduce the risk of cardiovascular events and 
improve quality of life in patients treated for CHD however evidence suggests that the 
management of such patients is sub-optimal with under-prescription of cardiac 
medications commonplace (Kotseva et al., 2009). This evaluation aims to determine 
whether patients attending cardiac rehabilitation demonstrate myocardial ischemia 
when exercise tested and whether this can be related to under-prescription of 
medications. 
 
101 exercise tests were retrieved retrospectively from patient’s rehabilitation notes. 35 
patients had been treated with medical management whereas 64 patients had 
additionally received revascularisation with PCI. A sub-maximal 12 lead ECG 
treadmill test had been completed which followed the modified BRUCE protocol. 
Baseline physiological measures, repeated at peak exercise were retrieved. An 
independent t-test was used to determine if there was a significant difference in peak 
ST-segment depression between the two treatment groups and spearman’s rank 
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correlations were performed to assess for relationships between ST-segment 
depression, physiological variables and the dose of cardiac medications prescribed. 
 
Patients who received medical management alone demonstrated greater ST-segment 
depression during exercise than those who were revascularised (p = .015). 
Relationships were also found between lower doses of bisoprolol and greater peak 
ST-segment depression (p = .009) and higher resting HR (p = .035). However no 
relationship was found between bisoprolol and peak HR or between the dose of 
ramipril and blood pressure at rest or peak. 
 
The results confirm the sub-optimal management of cardiac rehabilitation patients and 
suggest that optimisation of medical therapy is likely to improve outcomes. The 
evaluation confirms the place of the exercise ECG as an integrated component of the 
cardiac rehabilitation service and provides evidence for the need for a non-medical 
nurse prescriber within rehabilitation providing this is a cost-effective alternative to 
improving communication with general practitioners. 
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Introduction  
Cardiovascular disease (CVD) remains 
the leading cause of death in the UK, 
responsible for 46,000 premature 
deaths in 2010 (British Heart 
Foundation, 2012) although 30 day 
post myocardial infarction (MI) fatality 
has reduced from approximately 42% 
to 30% since 2002 (Smolina et al., 
2012), likely due to advancements to 
primary and secondary prevention 
including increased prescriptions of 
cardio-protective medications and 
increased use of percutaneous coronary 
interventions (PCI) to treat ST-
segment elevation MI. 
 
Evidence however suggests that the 
management of patients with CHD is 
sub-optimal and in particular, the 
under prescription of cardiac 
medications compared to that known to 
be effective from clinical research. 
56% of patients are reported to remain 
hypertensive six months after 
diagnosis and 51% have total serum 
cholesterol above 4.5mmol/l (Kotseva 
et al., 2009). Additionally, only a 
quarter of patients prescribed anti-
hypertensive medications achieve 
blood pressures targets, remaining at 
risk of secondary events.  
 
Achieving safe and effective optimal 
medical management, particularly 
following acute MI is challenged by 
shortened hospital stays. Nevertheless, 
initiation of an angiotensin-converting 
enzyme (ACE) inhibitor, beta-blocker, 
dual anti-platelet therapy and statin 
following acute MI is recommended 
(NICE, 2013) and guidance now 
recommends that instruction on the 
titration of these medications after 
discharge be included on hospital 
discharge summaries. 
 
Optimal medical management may 
also include revascularisation with PCI 
however, Boden et al. (2007) provides 
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evidence that the management of these 
patient may also be sub-optimal, 
reporting a high initial success rate 
however 34% of patients have angina 
one year later due to residual CHD 
resulting from either re-stenosis or 
deterioration of the disease in other 
lesions. Medical management is 
therefore required in conjunction with 
PCI to slow the progression of the 
disease. 
 
Comprehensive cardiac rehabilitation 
has additionally been shown to reduce 
all-cause mortality by 13% and cardiac 
specific deaths by 26% (Heran et al., 
2011) and 43% of patients receive 
rehabilitation following MI, PCI and 
CABG. In spite of such benefits, 
exercise based rehabilitation may act 
as a trigger for myocardial ischemia or 
cardiac arrest in patients with CHD 
(Haskell, 1978) therefore exercise 
testing and risk stratification prior to 
commencement is recommended 
(BACPR, 2012). Heart rate (HR), 
blood pressure and symptom 
monitoring are typically obtained 
during exercise testing although, aside 
from calculating the rate pressure 
product (RPP), information is 
generally not obtained to assess for 
ischemic compromise during exertion 
by means of ECG monitoring. 
 
‘Optimal medical management’ aims 
to reduce the risk of cardiovascular 
events, improve quality of life and 
optimise exercise capacity without 
restriction (Braunwald et al., 2000). 
Unique to cardiac rehabilitation at 
Wirral Heart Support Centre, patients 
undergo ECG treadmill exercise 
testing, allowing for the monitoring of 
ST-segment changes during exertion 
aimed to establish if restrictions such 
as ischemic thresholds are needed to 
exercise prescriptions, as 
recommended by the American 
College of Sports Medicine (2014). 
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Methods 
The University of Chester, Faculty of 
Life Sciences Research Ethics 
Committee and Wirral Community 
NHS Trust approved the protocol of 
the service evaluation. 
 
Participants 
180 patients were selected at random 
who had attended the gym at Wirral 
Heart Support Centre as part of their 
cardiac rehabilitation between 2010 
and 2014 following a diagnosis of 
cardiac conditions eligible according to 
the BACPR (2012) standards and 
therefore had clinical notes accessible 
within the department for review. 
Patients were included in the 
evaluation if they had a diagnosis of 
CHD and/or MI and had received 
treatment with medical management 
with or without revascularisation with 
PCI. Patients were excluded if their 
diagnosis was not related to CHD or if 
their treatment or diagnoses made 
interpretation of the ST-segment 
during exercise inaccurate. 
 
Research Design 
The aim of the service evaluation was 
to compare patients who have received 
medical management for CHD with 
those who additionally receive 
revascularisation with PCI to 
determine if there is evidence of 
myocardial ischemia following 
treatment. Evidence of myocardial 
ischemia was determined by ST-
segment depression on an exercise 
ECG treadmill test, performed 
routinely as part of the patient’s 
rehabilitation. Secondly, in order to 
establish whether patients’ 
management is sub-optimal, the 
evaluation aims to assess whether the 
degree of ST-segment depression 
observed is related to the prescription 
and dose of cardio-protective 
medications recommended by NICE 
(2013). 
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Patients completed a sub-maximal 
treadmill exercise test prior to 
participating in a community based 
supervised exercise programme as part 
of their Phase III cardiac rehabilitation. 
Exercise testing followed the modified 
BRUCE protocol, was symptom 
limited and achievement of sub-
maximal exertion was defined as a 
rating of perceived exertion (RPE) 15 
and/or a heart rate of 80% heart rate 
reserve (HRR). 
 
Measurement Procedures 
Exercise testing was performed in 
accordance with the department’s 
procedure for prescriptive exercise 
testing, led by either a competent 
cardiac rehabilitation nurse or exercise 
physiologist. Baseline measurements 
were taken at the start of the exercise 
test which included medications and 
their doses; medical history, treatment 
method, current symptoms of angina, 
resting ECG including resting level of 
ST-segment depression, resting heart 
rate (HR), resting systolic (SBP) and 
diastolic (DBP) blood pressure, 
measured with a calibrated, manual 
sphygmometer. A 12 lead ECG was 
recorded throughout the test using a 
calibrated CASE machine connected to 
a T-1200 treadmill (GE medical, US) 
and ECG lead placement followed the 
Mason-Likar system. RPE was 
recorded using the Borg (6-20) scale. 
HR and blood pressure were recorded 
at the end of each stage and myocardial 
oxygen consumption was subsequently 
estimated using a rate-pressure product 
(heart rate x SBP). Sub-maximal 
exercise capacity was expressed in 
units of metabolic equivalents 
(METS).   
 
Data Analysis 
As the assumptions for parametric data 
were met, analysis of difference in 
peak ST-segment depression between 
the two groups was performed using an 
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independent t-test and in order to 
demonstrate a significant difference 
between groups, p ≤ .05. The 
relationship between ST-segment 
depression and dose of cardiac specific 
medications was analysed using a 
spearman’s rank correlation as the data 
failed the assumptions of parametric 
data. Normality assumptions were 
verified with the K-Smirnoff test and 
homogeneity of variance with the 
Levene’s Statistic. All statistical 
analyses were performed using a 
statistical software package (SPSS, 
version 21, Chicago, IL, USA).  
 
Results 
180 patient notes were reviewed for 
inclusion in the evaluation and 79 
patients were subsequently excluded, 
the reasons for which are summarised 
in Table 1.  
 
 
 
Table 1. Exclusion criteria. 
101 
patients 
were 
deemed suitable for the evaluation, of 
which 64 had received 
revascularisation with PCI and 
concomitant medical management and 
35 had received medical management 
alone. Additionally, 36 patients had a 
primary diagnosis of CHD, 35 STEMI, 
27 NSTEMI, and 3 had been diagnosed 
with acute coronary syndrome (ACS). 
The characteristics of both groups are 
summarised in Table 2 (results are 
expressed as mean ± SD unless 
otherwise stated). 12% of patients had 
been experiencing symptoms of angina 
(42% were treated with PCI, 58% 
medical management) whereas 88% 
felt they were asymptomatic. Of the 12 
patients experiencing angina, 50% 
demonstrated clinically significant ST-
segment depression on the exercise 
test. 
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Table 2. Patient characteristics and 
exercise testing measurements. 
ST-
segment 
depression  
The results of an independent t-test 
demonstrate a significant (p = .015) 
difference in the level of ST-segment 
depression recorded at peak exercise 
between the two treatment groups. 
Consultation of the descriptive 
statistics reveals that patients treated 
with medical management alone 
demonstrated greater levels of peak 
ST-segment depression (-0.73 ± 
.59mm) compared to those treated with 
medical management and 
revascularisation with PCI (-0.44 ± 
.55mm). Furthermore, 24% of patients’ 
demonstrated clinically significant 
levels of ST-segment depression 
(defined as ≥ -1.00mm, horizontal or 
down sloping depression) of which 11 
had been treated with PCI and 13 with 
medical management. The estimated 
myocardial work (expressed as RPP) at 
peak exercise was also greater amongst 
patients treated with medical 
management compared to PCI (178 ± 
37.6 vs. 169 ± 37.8bpm.mmHg, 
respectively).  
 
Cardio-protective therapies 
A significant, positive relationship was 
found between the dose of bisoprolol 
prescribed and peak ST-segment 
depression during exercise testing (p = 
.009, r = .259), therefore low dose 
bisoprolol was associated with greater 
levels of ST-segment depression. 
Bisoprolol dose was also significantly 
related to resting heart rate (p = .035, r 
= -.210) therefore larger doses of 
bisoprolol were associated with a 
lower resting heart rate. There was 
however no significant relationship 
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between dose of bisoprolol and HR at 
peak exercise (p = .069, r = -.182). No 
significant relationships were 
demonstrated with the dose of ramipril 
and resting SBP (p = .659), peak SBP 
(p = .616), resting DBP (p = .277) and 
peak DBP (p = .608). 
 
Discussion 
The results of this evaluation 
demonstrate that patients managed 
conservatively with medications alone 
demonstrate significantly greater levels 
of ST-segment depression when 
exercise tested compared to those who 
are additionally re-vascularised with 
PCI. The results are comparable to 
research from Davies et al. (1997) 
whereby initial revascularisation 
improved two-year prognosis in 
patients with evidence of ischemia, 
even if angina was controlled on 
conservative medical therapy.  
 
The results also demonstrate that 
patients treated with PCI were able to 
exercise for longer before reaching 
fatigue and achieved a greater METs 
level during the sub-maximal test than 
those treated with medical 
management. Myers (2003) reports 
exercise capacity between 1 and 6 
METs to represent a greater relative 
risk of death than greater capacities. 
This indicator of fitness level has 
additionally been shown to be more 
predictive of death than other well 
known risk factors for CHD. The 
present evaluation demonstrates 
comparable measures of average 
resting heart rate and blood pressure 
for the two groups which would not 
have been defined as tachycardia or 
hypertensive according to the NICE 
clinical guidelines (2011) and would 
not have indicated the need for 
restriction to exercise prescription in 
the absence of information from an 
ECG. Previous research does however 
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appear to use measures of heart rate, 
blood pressure and blood cholesterol as 
key measurement of risk factor 
management rather than measures of 
fitness and ST-segment depression 
such as Teo et al. (2009) who found 
the addition of PCI to optimal medical 
management did not improve nor did it 
worsen clinical outcomes including all-
cause mortality and nonfatal MI in 
patients with stable CHD. 
 
The heart rate recovery after exercise 
testing has also been demonstrated as 
independently predictive of cardiac 
mortality. Vivekananthan et al. (2003) 
performed symptom-limited exercise 
testing for patients with suspected 
CAD followed by invasive coronary 
angiography. The heart rate recovery 
was abnormal if it reduced ≤12 
beats/min during the first minute after 
peak exercise and the mortality risk of 
an abnormal recovery rate was 
comparable to having severe CHD. 
The reduction in heart rate after 
exercise represents the withdrawal of 
the sympathetic nervous system and 
reactivation of parasympathetic 
nervous system however reduced vagal 
tone can adversely affect mortality. In 
this evaluation, the average heart rate 
recovery for patients treated with PCI 
was greater (17beats/min) than those 
treated with medications (14beats/min) 
and again suggesting that patients are 
at lower risk of adverse events if 
treated with PCI and medical 
management. 
 
Conversely, an almost equal number of 
patients from each treatment group 
demonstrated clinically significant 
levels of ST-segment depression on 
their exercise test and therefore 
according to guidelines from the 
ACSM (2014), require restrictions to 
their exercise prescription for cardiac 
rehabilitation. This does therefore 
suggest that both management 
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strategies demonstrate evidence of sub-
optimal management, reiterating that 
medical therapy and PCI should be 
viewed as complementary rather than 
opposing management strategies. 
Although angioplasty improves 
coronary blood flow, the treatment is 
restricted to specific vessels, therefore 
all patients would benefit from 
comprehensive risk factor control with 
concomitant optimal medical therapy. 
As such, this evaluation also sought to 
determine if the level of ST-segment 
depression can be related to a lack of 
optimisation of cardiac medications.  
 
The results confirm that greater doses 
of the beta-blocker medication 
bisoprolol were associated with 
reduced significance of ST-segment 
depression during exercise testing. The 
average dose of bisoprolol was also 
greater amongst patients treated with 
PCI however, the average dose of both 
groups was relatively low in 
comparison to evidence that suggests 
the treatment is most effective when 
prescribed at the highest tolerated dose 
(Viskin et al., 1995), whereas the lower 
doses prescribed to patients in this 
evaluation appear typical of hospital 
discharge doses. The results also 
demonstrate that lower resting heart 
rates were associated with greater 
doses of bisoprolol and those treated 
with PCI demonstrated an average 
lower resting heart than those treated 
with medical management. This is 
particularly significant given that 
research reports one-year mortality as 
significantly increased in patients with 
a resting heart rate ≥ 67bpm 
(Umbrasiene, Ventsloviene & 
Babarskiene, 2011) which based on 
this parameter alone would suggest 
patients receiving medical 
management alone are at greater risk 
of mortality.  
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These results suggest that patient 
outcomes could be improved through 
the up-titration of beta-blockers 
however it is appreciated that this 
process is far from simplistic. Despite 
the evaluation being unable to 
comment on the reasons why the doses 
of bisoprolol were not optimised, 
typical reasons for the lack of 
optimisation of medications post-MI 
include the presence of contra-
indications such as asthma, previous 
cerebrovascular accidents or symptoms 
of dizziness, dyspnoea and lethargy 
(Ong et al., 2012). Although, as the 
average time from MI to exercise 
testing in this evaluation was between 
17 and 24 weeks, patients would have 
therefore had the opportunity for up-
titration in the community had this 
been available and appropriate. 
Although NICE (2013) do not specify 
optimal timings of titration of beta 
blockers due to a lack of clinical 
evidence, they do recommend 
communication of titration plans in 
discharge summaries therefore it is 
feasible to consider that external 
factors such as poor communication 
between primary and secondary care 
and patient education could contribute 
to the results reported. 
 
The role of a nurse prescriber in 
cardiac rehabilitation is a relatively 
new concept however the results of 
this evaluation provides evidence for 
its potential usefulness. Although with 
increasing pressures on staff within the 
NHS to work more cost-effectively this 
could affect the utilisation of such a 
service. It could therefore be argued 
whether cardiac rehabilitation staff can 
improve communication with general 
practitioners in order to facilitate the 
optimal management of patient 
medications. This could provide a 
more viable option initially than 
training nurses in non-medical 
prescribing in addition to providing 
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time for the conduction of 
appointments to ensure safe titration 
without compromise to the normal 
delivery of the service. Furthermore, 
those patients who do not attend or 
complete rehabilitation still require the 
same community monitoring as those 
who attend which emphasises the 
importance of ensuring information is 
communicated effectively on discharge 
summaries so that general practitioners 
can take responsibility for patient 
compliance and monitoring.   
 
As the majority of patients were 
asymptomatic and therefore 
demonstrated silent ischemia, this also 
provides a rationale for the place of 
ECG exercise testing in cardiac 
rehabilitation as without this level of 
information, exercise prescription 
would be solely based on symptom 
monitoring and risk factor 
management. Furthermore, if 
individuals attending cardiac 
rehabilitation are sub-optimally 
medically managed, this negatively 
impacts the scope to safely prescribe 
beneficial exercise in cardiac 
rehabilitation due to potentially low 
ischemic burdens. ACSM (2014) 
guidelines define ischemic thresholds 
as exercise of 10beats/min below the 
heart rate at which clinically 
significant ST-segment depression was 
observed. However, Noel et al. (2007) 
challenge the guidelines in their 
randomised control trial of patients 
treated for CHD who either exercised 
above this threshold or adhered to 
current guidelines. Prolonged aerobic 
exercise inducing ST-segment 
depression between 1.0 and 2.1mm 
was not found to result in significant 
arrhythmias, impairments to left 
ventricular function or indications of 
myocardial injury.  
 
Additionally, Miranda et al. (1991) 
report from a large study of patients 
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who underwent exercise testing 
followed by diagnostic angiography 
that exercise induced ST-segment 
depression is a better marker for CAD 
than that of exercise induced angina 
however ECG monitoring is not 
routinely used to evaluate low risk, 
asymptomatic cardiac rehabilitation 
patients and it can be argued whether 
safety to exercise could be achieved 
using cheaper alternatives such as by 
use of walking assessments which 
require less staff, time and equipment 
whilst being reliable. Although, the use 
of a six minute walking test (6MWT) 
has been criticised as merely 
measuring distance walked and 
symptoms as opposed to physiological 
parameters of blood pressure that can 
be used as indicators of aerobic 
capacity (Simms et al., 2007). 
Incremental shuttle walking has 
however been shown to be safe in 
patients with CHD and report a low 
risk of cardiac events with stress 
testing of 0% to 0.36% (Jolly et al., 
2008) in addition to a low risk of 
adverse events during rehabilitation 
classes.  
 
Pepera, Bromley & Sandercock (2013) 
also report only minor events provoked 
during incremental shuttle walking and 
ECG monitoring as part of cardiac 
rehabilitation, with the most significant 
event being silent myocardial 
ischemia. Although, low incidence 
rates with functional capacity testing 
may be a result of low individual effort 
and the study failed to report exact 
measures of ST-segment depression so 
it cannot be conferred whether the 
patients demonstrated clinically 
significant ischemia. Additionally, the 
ambulatory ECG monitoring was 
performed using a single lead whereas 
a 12 lead ECG provides additional 
information on the severity of the 
disease. The use of ambulatory ECG 
monitoring during exercise testing is 
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not commonplace in the UK despite 
the usefulness in identifying patients 
with the greatest risk of cardiovascular 
events during exercise however, the 
American Heart Association (Fletcher 
et al. 2001) clearly recommend the use 
of such monitoring in their guidance. 
 
Study limitations 
Some limitations of the evaluation 
should nevertheless be noted including 
that stress-induced myocardial 
ischemia is generally diagnosed on the 
basis of ST-segment changes, angina 
and ventricular arrhythmias however 
the author felt that analysis of 
arrhythmias was beyond the scope of 
this service evaluation. It is also 
recognised that the gold standard 
analysis of CHD is by the use of 
invasive coronary angiography and as 
such exercise testing has been less 
commonly used in the diagnostic 
management of patients with suspected 
CHD since the NICE (2010) chest pain 
guidelines were updated to utilise more 
accurate coronary imaging techniques. 
The sensitivity and specificity of 
exercise induced ST-segment 
depression is 68% and 77% 
respectively (Gibbons, 2002) with a 
range of 40% for one vessel disease 
and 90% for three vessel disease. If the 
exercise test had coupled the 12 lead 
ECG with cardio-pulmonary testing, 
this would have enabled more robust 
analysis of hemodynamic responses to 
exercise including oxygen uptake and 
the anaerobic threshold and therefore 
providing useful information for both 
CHD and heart failure patients. 
However, this would have implications 
on staffing and cost that would at 
present make it an unrealistic option 
for exercise testing cardiac 
rehabilitation patients. 
 
Additionally, patients treated with 
CABG were excluded from the 
evaluation which represents a large 
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portion of CHD patients however this 
was based on evidence of non specific 
ST changes post surgery that would 
have made the interpretation less 
reliable due to the nature of the 
surgery. New ECG abnormalities 
including ST-segment elevation, 
depression and T wave inversion after 
CABG appears more common than 
after PCI (Yokoyama et al., 2000) 
although the prognostic importance of 
the abnormalities is not well 
established. Nevertheless, the 
specificity of ST-segment depression 
as a marker of ischemia on exercise 
testing following CABG is reduced 
due to post operative pericardial 
trauma and electrolyte imbalance.  
 
Finally, Myers (2003) determined 
fitness levels for their study in terms of 
maximal exercise testing whereas the 
current analysis can only comment on 
fitness in terms of sub-maximal 
exertion. Myers (2003) additionally 
reports that the greatest reduction in 
mortality is seen when individuals 
increase their exercise capacity from ≤ 
6 METs to ≥ 8 METs. This sets a 
target for improvement to exercise 
capacity by the end of the 
rehabilitation however, the service 
does not currently repeat any form of 
exercise testing at the end of the 
programme due to cost and staffing 
implications. Despite the exercise test 
being completed at least 17 weeks post 
MI, the exercise rehabilitation then 
runs for a 12 week period after and the 
present evaluation is unable to 
compare outcomes from this exercise 
test to that of the end of rehabilitation. 
 
 
Conclusion 
It is evident that there are advantages 
and disadvantages to exercise 
screening with ECG treadmill testing, 
including that the presence of a doctor 
on site restricts its facilitation and as 
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patients may have already undergone 
stress tests in the diagnosis of their 
CHD, staff should be cautious of over 
medicalising the patient experience. 
Nevertheless, the test provides 
valuable information that cannot be 
conferred from functional capacity 
testing and until further research 
emerges to confirm the safety of 
exercise training above ischemic 
thresholds, the test will continue to 
have a place as a routine part of the 
patient journey. For patients 
demonstrating clinically significant 
levels of ST-segment depression, the 
exercise test is normally repeated after 
8 weeks of exercise training to enable 
comparison of such changes and 
physiological parameters including 
assessment of whether ischemic 
burdens occur at the heart rate and 
exercise intensity as previously noted. 
However, it could equally be argued 
that those who do not demonstrate 
clinically significant ST-segment 
depression at the beginning of the 12 
week programme may deteriorate 
however, due to the cost implications 
of repeating the test at the end of the 
programme on every patient, selection 
may need to be based on an individual, 
symptom monitored basis, using 
clinical judgement. Nevertheless, this 
evaluation has provided strong 
evidence for the need to optimise 
medical management to ensure patients 
achieve the best possible outcomes. 
Therefore the service should prioritise 
investigating how best to utilise the 
information received from exercise 
testing and ensure those who 
demonstrate clinically significant ST-
segment depression are assessed for 
potential up-titration of medications. 
Future evaluation within the 
department would be beneficial if 
comparing ST-segment depression at 
baseline and after 8 weeks of exercise 
training. This would also help to guide 
the targeting of medical management 
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and may provide evidence for the need 
of a nurse prescriber in rehabilitation 
in the future. It would also be 
worthwhile factoring changes to 
medications during the same time 
period into such analysis to confirm 
benefits of up-titration. However, until 
such information comes to light and 
whilst the service needs to demonstrate 
it’s cost effectiveness it may be 
worthwhile continuing to establish 
rigid procedures to facilitate better 
communication with general 
practitioners and consultants to enable 
effective up-titration of cardiac 
medications in the community. If this 
process appears to be unsuccessful or 
the timing of up-titration affected by 
poor communication, then this 
evaluation still provides evidence for 
the training of non-medical nurse 
prescribers who could integrate into 
the cardiac rehabilitation service.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
J02482 
 40
 
 
 
 
 
 
 
 
Faculty of Life Sciences 
Research Ethics Committee 
 
frec@chester.ac.uk 
 
 
 
 
 
 
Melanie Meadowcroft 
 
 
28th April 2014 
 
 
Dear Melanie, 
 
Study title: Are patients with coronary heart disease ‘optimally’ 
medically managed within cardiac rehabilitation?  A 
service evaluation.  
FREC reference: 892/14/MM/CSN 
Version number: 1 
 
Thank you for providing the documentation for the amendments recommended 
following the approval of the above application.  These amendments have been 
approved by the Faculty Research Ethics Committee.   
 
With the Committee’s best wishes for the success of this project. 
 
Yours sincerely, 
 
 
 
 
 
Dr. Stephen Fallows 
Chair, Faculty Research Ethics Committee 
J02482 
 41
MSc Data Collection: Wirral Heart Support Centre 
 
Patient Demographics (pg 1) 
 
      Age: _____ 
 
       
 
 
Diagnosis: CHD □ NSTEMI □ STEMI □ ACS □ HF □ Valve Disease □ 
Other _____________________________________ 
CHD Details: Vessel affected:_____________________________ 
 
LV function: Normal   Mildly impaired   Mod–severe  Unknown 
Treatment: Medical Management      PCI       PPCI      CABG 
  No. of stents/grafts __________ 
  Treatment Date        /         / 
Other _____________________________________ 
Medications: Beta Blocker   ___________________       (     )           
      ACE Inhibitor  ___________________       (      )               
      Statin          ___________________       (      )             
      Nitrates          ___________________       (      )         
      Other             ___________________       (      )         
Current Angina Symptoms:   Yes        No 
Resting ECG:  Sinus  AF  BBB  Paced 
Other _________________________________ 
 
Patient to be included in study 
Yes    No  Reason _____________________________ 
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ETT Data Collection (pg 2) 
 
Date of test:    /     /    
Time from event of ETT   ______________ 
Total Time completed of Mod Bruce: ______________ 
Symptoms of angina: Yes/No 
Max METS achieved: ________ 
 
 
 
Resting HR: _______ bpm   Resting BP: __________ mmHg 
 
Peak HR:     _______ bpm       Peak BP:     ___________ mmHg          
 
Peak RPE: _____                     Peak RPP:   ______ 
 
1 minute HR recovery: _____ bpm 
 
Resting ST depression:          ___________ mm None 
 
Peak exercise ST depression: ___________ mm       None 
 
ST depression in leads _______________________________ 
 
Ischemic threshold set:  Yes / No 
 
 
Data entered on SPSS  
Predicted Max HR Non-
Blocked 
→ 
 
Blocked 
→ 
 
80% HRR   
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